- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03838744
Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments. (TOMAS2)
September 12, 2023 updated by: Italian Sarcoma Group
Phase 2 Randomized Trial of Trabectedin + Olaparib vs. Trabectedin in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.
Phase II study in patient with advanced Soft Tissue Sarcoma (STS) patients who have already received or are not suitable, for a doxorubicin-based treatment.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Randomized, open-label, active-controlled, multicenter phase II clinical study.
Patients will be randomly assigned in a 1:1 ratio to receive trabectedin 1.1 mg/m2 24-hour intravenous continuous infusion every 3 weeks with olaparib (per os) 150 mg twice a day versus trabectedin 1.5 mg/m2 intravenous 24-hour continuous infusion every 3 weeks until progression or unacceptable toxicity as second- or further-line treatment in a population of STS patients who have already received or are not suitable for a doxorubicin-based treatment.
Study Type
Interventional
Enrollment (Estimated)
126
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bologna, Italy, 40136
- Istituto Ortopedico Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors
-
Padova, Italy
- IRCCS Istituto Oncologico Veneto (IOV)
-
Roma, Italy, 00144
- Istituto Nazionale Tumori Regina Elena - Unit of Medical Oncology I
-
-
BO
-
Bologna, BO, Italy, 40139
- Azienda Ospedaliero-Universitaria di Bologna
-
-
FC
-
Meldola, FC, Italy
- I.R.S.T. di Meldola
-
-
Firenze
-
Prato, Firenze, Italy, 59100
- Nuovo Ospedale di Prato
-
-
MI
-
Milano, MI, Italy, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Milano, MI, Italy, 20141
- Istituto Europeo Di Oncologia
-
-
PA
-
Palermo, PA, Italy, 90127
- Azienda ospedaliera universitaria paolo giaccone
-
-
PD
-
Aviano, PD, Italy, 33081
- Centro di Riferimento Oncologico di Aviano
-
-
RM
-
Roma, RM, Italy, 00128
- Policlinico Universitario Campus Biomedico
-
-
TO
-
Torino, TO, Italy
- Ospedale San Giovanni Bosco
-
-
Torino
-
Candiolo, Torino, Italy, 10060
- Fondazione del Piemonte per l'Oncologia IRCC Candiolo
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Provision of written informed consent prior to any study specific procedures.
- Patients with histologically documented and not surgically resectable or metastatic STS that progressed after first- or further-line treatments for relapsing disease.
- At least one previous line of anthracycline-containing chemotherapy for advanced disease or relapsed/progressed within six months of a previous treatment with an anthracycline-containing chemotherapy in the neo-adjuvant/adjuvant setting.
- Central revision will be mandatory in order to enroll a patient. Central revision will assess both diagnosis and adequacy of tumor specimen (minimum requisite will be a formalin-fixed paraffin-embedded block of either a 16-gauge tru-cut biopsy or a non-necrotic surgical tumor specimen). The patient has to consent BReast CAncer genes 1 and 2 (BRCA1 and BRCA 2) evaluation in the interest of avoiding misleading interpretation of resulting data.
- Measurable disease according Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. Patients with an ECOG 2 are eligible if it depends solely on orthopedic problems.
- Estimated life expectancy of at least 16 weeks.
- Age ≥18 years.
- Left Ventricular Ejection Fraction ≥ 50% and/or above lower institutional limit of normality
- Adequate bone marrow, liver and renal function assessed within 7 days prior to
- Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on day 1
Exclusion Criteria:
- Previous enrolment in the present study
- Participation in another clinical study with an investigational product during the last 4 weeks.
- Previous treatment with trabectedin, olaparib or other Poly Adpribose polymerase 1 (PARP-1) inhibitors or analogue.
- Persistent toxicities (≥ grade 2 according Common Terminology Criteria for Adverse Events - CTCAE) with the exception of alopecia, caused by previous anticancer therapies.
- Dementia or significantly altered mental status (e.g., psychiatric disorder) that would prevent the understanding or rendering of informed consent and compliance with the requirements of this protocol.
- Patients with any severe and/or uncontrolled medical conditions such as unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤ 6 months, serious uncontrolled cardiac arrhythmia, uncontrolled hyperlipidemia, active or uncontrolled severe infection, cirrhosis, chronic or persistent active hepatitis or severely impaired lung function. In particular for history of cardiac disease: congestive heart failure >New York Hearth Association (NYHA) class 2; active coronary artery disease (myocardial infarction more than 6 months prior to study entry is allowed); cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension, unstable spinal cord compression (untreated and unstable for at least 28 days prior to study entry), superior vena cava syndrome, extensive bilateral lung disease.
- Immunocompromised patients, e.g., patients who are known to be serologically positive for Human Immunodeficiency Virus (HIV).
- Active clinically serious infections (> grade 2 CTCAE).
- Active viral hepatitis [Hepatitis B Virus - (HBV) or Hepatitis C Virus (HCV) infection]
- Metastatic brain or meningeal tumors (unless the patient is > 6 months from definitive therapy, does not require corticosteroid treatment, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry). Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days.
- Patients with seizure disorders requiring medication (such as steroids or anti-epileptics).
- Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 28 days before the start of treatment. Pregnancy test will be repeated and confirmed on cycle 1 day 1 before treatment start. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and 5 months after last dose of study drug.
- Patients with evidence or history of bleeding diathesis.
- Patients undergoing renal dialysis.
- Patients unable to swallow oral medications.
- Uncontrolled diabetes (fasting glucose > 2 x Upper Normal Limit).
- Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent (except corticosteroids with a daily dosage equivalent to prednisone ≤ 20 mg for adrenal insufficiency). Topical or inhaled corticosteroids are permitted.
- Other malignancy unless curatively treated with no evidence of disease for ≥5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ , Stage 1, grade 1 endometrial carcinoma. Patients with a history of localised triple negative breast cancer may be eligible, provided they completed their adjuvant chemotherapy more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease
- Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. impairment of gastrointestinal (GI) function, or GI disease that may significantly alter the absorption of the study drugs).
- Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of study entry
- Radiotherapy during study or within 3 weeks of start of study drug. (Palliative radiotherapy will be allowed).
- Major surgery within 4 weeks of start of study. Thus, patients must have recovered from wound or directly surgical related complications at time of study randomization.
- Investigational drug therapy outside of this trial during or within 4 weeks of study entry.
- Patients with known hypersensitivity to trabectedin, olaparib or to their excipients.
- Patients can receive a stable dose of bisphosphonates for bone metastases before and during the study as long as these were started at least 4 weeks prior to treatment with the study drugs.
- Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
- A history of noncompliance to medical regimens or inability or unwillingness to return for scheduled visits.
- Resting ElectroCardioGram (ECG) indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (eg., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, corrected QT prolongation >500 ms, electrolyte disturbances, etc.), or patients with congenital long QT syndrome.
- Concomitant use of known strong CYtochromeP3A (CYP3A) inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting study drugs is 2 weeks.
- Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort ) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting study drugs is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
- Previous allogenic bone marrow transplant or double umbilical cord blood transplantation
- Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of them
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard arm: Trabectedin in monotherapy
Trabectedin in monotherapy at the dose 1.5 or 1.3 mg/m2 (according institutional practice) given as intravenous infusion at day 1 every 3 weeks (21 days cycle)
|
Trabectedin in monotherapy
Other Names:
|
Experimental: Experimental arm: Trabectedin + Olaparib
Trabectedin at the dose 1.1mg/m2 given as intravenous infusion at day 1 every 3 weeks (21 days cycle) plus Olaparib per os at the dose of 150 mg twice a day
|
Trabectedin given in combination to olaparib
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free Survival (PFS)
Time Frame: At 6 months
|
Survival without disease progression
|
At 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: At 3 years
|
Survival from the first dose treatment to death for any cause
|
At 3 years
|
Overall Survival rate
Time Frame: At 12 months
|
Proportion of patients who are still alive at 12 months after have started the treatment
|
At 12 months
|
Progression free Survival (PFS)
Time Frame: At 3 years
|
Survival without disease progression
|
At 3 years
|
Progression free Survival Rate
Time Frame: At 6 months
|
Proportion of patients who did not progress at 6 months after have started the treatment
|
At 6 months
|
Growth Modulation Index (GMI)
Time Frame: Week 6, week 12, week 18, week 27, week 36
|
Ratio of time to progression with the nth line of therapy to the those with the n-1th line.
|
Week 6, week 12, week 18, week 27, week 36
|
Adverse events related to the treatment
Time Frame: Week 3, week6, week 9, week 12, week 18, week 27, week 36
|
Safety in term of adverse event is evaluate from the firs treatment dose throughout the study according to CTCAE 5.0
|
Week 3, week6, week 9, week 12, week 18, week 27, week 36
|
Quality of Life according the 30 questions European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC Quality of Life Questionnaire C30)
Time Frame: Week 3, week6, week 9, week 12, week 18, week 27, week 36
|
Evaluation of the quality of life collected with EORTC Quality of Life Questionnaire C30
|
Week 3, week6, week 9, week 12, week 18, week 27, week 36
|
Quality of Life according the questionnaire Euro Quality Of Life 5 Domains (EQ-5D)
Time Frame: Week 3, week6, week 9, week 12, week 18, week 27, week 36
|
Evaluation of the quality of life collected with EQ-5D
|
Week 3, week6, week 9, week 12, week 18, week 27, week 36
|
Over all Response Rate
Time Frame: At week 18
|
Overall response rate according Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
|
At week 18
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Giovanni Giovanni, MD, Fondazione del Piemonte IRCCS di Candiolo
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25. Erratum In: Lancet Oncol. 2017 Sep;18(9):e510.
- Grignani G, D'Ambrosio L, Pignochino Y, Palmerini E, Zucchetti M, Boccone P, Aliberti S, Stacchiotti S, Bertulli R, Piana R, Miano S, Tolomeo F, Chiabotto G, Sangiolo D, Pisacane A, Dei Tos AP, Novara L, Bartolini A, Marchesi E, D'Incalci M, Bardelli A, Picci P, Ferrari S, Aglietta M. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. Lancet Oncol. 2018 Oct;19(10):1360-1371. doi: 10.1016/S1470-2045(18)30438-8. Epub 2018 Sep 11.
- Samuels BL, Chawla S, Patel S, von Mehren M, Hamm J, Kaiser PE, Schuetze S, Li J, Aymes A, Demetri GD. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol. 2013 Jun;24(6):1703-9. doi: 10.1093/annonc/mds659. Epub 2013 Feb 5.
- Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016 Nov;17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X. Epub 2016 Sep 9.
- Merlini A, Centomo ML, Ferrero G, Chiabotto G, Miglio U, Berrino E, Giordano G, Brusco S, Pisacane A, Maldi E, Sarotto I, Capozzi F, Lano C, Isella C, Crisafulli G, Aglietta M, Dei Tos AP, Sbaraglia M, Sangiolo D, D'Ambrosio L, Bardelli A, Pignochino Y, Grignani G. DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination. Front Oncol. 2022 Aug 30;12:844250. doi: 10.3389/fonc.2022.844250. eCollection 2022.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 26, 2020
Primary Completion (Estimated)
February 1, 2025
Study Completion (Estimated)
February 1, 2025
Study Registration Dates
First Submitted
February 11, 2019
First Submitted That Met QC Criteria
February 11, 2019
First Posted (Actual)
February 12, 2019
Study Record Updates
Last Update Posted (Actual)
September 13, 2023
Last Update Submitted That Met QC Criteria
September 12, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ISG-TOMAS 2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Soft Tissue Sarcoma
-
University of WashingtonAadi Bioscience, Inc.Active, not recruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States
-
Grupo Espanol de Investigacion en SarcomasRecruitingAdvanced Solid Tumor | Advanced Soft-tissue Sarcoma | Advanced L-sarcomas | Other Advanced Sarcomas | Localized Soft-tissue SarcomaSpain
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.TerminatedAdvanced Cancer | Advanced Soft-tissue SarcomaChina
-
Massachusetts General HospitalJazz PharmaceuticalsRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue Sarcoma | Advanced Leiomyosarcoma | Leiomyosarcoma MetastaticUnited States
-
CytRxUnknownUnresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States, Australia, Russian Federation, Hungary, India, Romania, Ukraine
-
Epizyme, Inc.RecruitingAdvanced Soft-tissue Sarcoma | Advanced Epithelioid SarcomaUnited States, Taiwan, Canada, United Kingdom
-
Centre Leon BerardNovartis; National Cancer Institute, FranceRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
-
UNICANCERRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
-
University of Colorado, DenverAgenus Inc.RecruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue SarcomaUnited States
Clinical Trials on Standard arm: Trabectedin in monotherapy
-
PfizerCompletedNon-Alcoholic Fatty Liver Disease (NAFLD)United States
-
Indiana UniversityRecruitingNASH - Nonalcoholic Steatohepatitis | Cirrhosis, LiverUnited States
-
Herning HospitalCompletedRehabilitationDenmark
-
University of NebraskaRecruitingHemiplegic Cerebral PalsyUnited States
-
Italian Sarcoma GroupPharmaMarRecruitingSoft Tissue Sarcoma | Leiomyosarcoma of OvaryItaly
-
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Shanghai Public Health Clinical Center; Wuhan Union Hospital, China; Beijing... and other collaboratorsCompletedTuberculosis DiagnosisChina
-
Instituto de Investigacion Sanitaria La FeMedtronicUnknown
-
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Shanghai Public Health Clinical Center; Air Force Military Medical University... and other collaboratorsCompleted
-
Bryan Schneider, MDHoosier Cancer Research Network; Walther Cancer Institute; Vera Bradley Foundation... and other collaboratorsCompletedBreast Cancer | Malignant Neoplasm of BreastUnited States
-
Tata Memorial HospitalRecruiting